Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 77Tumor-Agnostic 8Breast 6Thoracic 5Gastrointestinal 5CNS 4Head & Neck 3Sarcoma 2Other solid neoplasm 2Gynecologic 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Endocrine 1Classical hematology 1

Conditions

Oligodendroglioma 1Liposarcoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Radiotherapy 220Doxorubicin 210Cyclophosphamide 210Temozolomide 182Ifosfamide 121Filgrastim 111Imatinib Mesylate 104Etoposide 101Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 80Irinotecan 79pembrolizumab 75Radiation 69Carboplatin 65Methotrexate 62pazopanib 61Nivolumab 58Cisplatin 58fludarabine phosphate 57Peripheral Blood Stem Cell Transplantation 57Surgical Procedures, Operative 56Specimen Handling 56Trabectedin 52Docetaxel 50Biopsy 50Busulfan 49Melphalan 46Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
cabazitaxel × Sarcoma × Clear all
NCT01913652 2021-09-14

Ph II Cabazitaxel DD Liposarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
42 enrolled
Sarcoma

Liposarcoma

NCT01740570 2018-01-19

Phase I/II Cabazitaxel for Recurrent Malignant Glioma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡